Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma : a phase I trial
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining healthy donor FMT with the PD-1 inhibitors nivolumab or pembrolizumab in 20 previously untreated patients with advanced melanoma. The primary end point was safety. No grade 3 adverse events were reported from FMT alone. Five patients (25%) experienced grade 3 immune-related adverse events from combination therapy. Key secondary end points were objective response rate, changes in gut microbiome composition and systemic immune and metabolomics analyses. The objective response rate was 65% (13 of 20), including four (20%) complete responses. Longitudinal microbiome profiling revealed that all patients engrafted strains from their respective donors; however, the acquired similarity between donor and patient microbiomes only increased over time in responders. Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. Our results show that FMT from healthy donors is safe in the first-line setting and warrants further investigation in combination with immune checkpoint inhibitors. ClinicalTrials.gov identifier NCT03772899.
| Errataetall: |
CommentIn: Nat Med. 2023 Aug;29(8):1910-1911. - PMID 37420098 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 8 vom: 06. Aug., Seite 2121-2132 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase I |
|---|
| Anmerkungen: |
Date Completed 17.08.2023 Date Revised 05.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT03772899 CommentIn: Nat Med. 2023 Aug;29(8):1910-1911. - PMID 37420098 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02453-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359160077 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359160077 | ||
| 003 | DE-627 | ||
| 005 | 20231226080302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02453-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359160077 | ||
| 035 | |a (NLM)37414899 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Routy, Bertrand |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma |b a phase I trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2023 | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03772899 | ||
| 500 | |a CommentIn: Nat Med. 2023 Aug;29(8):1910-1911. - PMID 37420098 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining healthy donor FMT with the PD-1 inhibitors nivolumab or pembrolizumab in 20 previously untreated patients with advanced melanoma. The primary end point was safety. No grade 3 adverse events were reported from FMT alone. Five patients (25%) experienced grade 3 immune-related adverse events from combination therapy. Key secondary end points were objective response rate, changes in gut microbiome composition and systemic immune and metabolomics analyses. The objective response rate was 65% (13 of 20), including four (20%) complete responses. Longitudinal microbiome profiling revealed that all patients engrafted strains from their respective donors; however, the acquired similarity between donor and patient microbiomes only increased over time in responders. Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. Our results show that FMT from healthy donors is safe in the first-line setting and warrants further investigation in combination with immune checkpoint inhibitors. ClinicalTrials.gov identifier NCT03772899 | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Lenehan, John G |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Wilson H |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Jamal, Rahima |e verfasserin |4 aut | |
| 700 | 1 | |a Messaoudene, Meriem |e verfasserin |4 aut | |
| 700 | 1 | |a Daisley, Brendan A |e verfasserin |4 aut | |
| 700 | 1 | |a Hes, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Al, Kait F |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Gili, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Punčochář, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Ernst, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Logan, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Belanger, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Esfahani, Khashayar |e verfasserin |4 aut | |
| 700 | 1 | |a Richard, Corentin |e verfasserin |4 aut | |
| 700 | 1 | |a Ninkov, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Piccinno, Gianmarco |e verfasserin |4 aut | |
| 700 | 1 | |a Armanini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnamoorthy, Mithunah |e verfasserin |4 aut | |
| 700 | 1 | |a Figueredo, Rene |e verfasserin |4 aut | |
| 700 | 1 | |a Thebault, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Takis, Panteleimon |e verfasserin |4 aut | |
| 700 | 1 | |a Magrill, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Ramsay, LeeAnn |e verfasserin |4 aut | |
| 700 | 1 | |a Derosa, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesi, Julian R |e verfasserin |4 aut | |
| 700 | 1 | |a Parvathy, Seema Nair |e verfasserin |4 aut | |
| 700 | 1 | |a Elkrief, Arielle |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Ian R |e verfasserin |4 aut | |
| 700 | 1 | |a Lapointe, Rejean |e verfasserin |4 aut | |
| 700 | 1 | |a Segata, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Haeryfar, S M Mansour |e verfasserin |4 aut | |
| 700 | 1 | |a Mullish, Benjamin H |e verfasserin |4 aut | |
| 700 | 1 | |a Silverman, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, Jeremy P |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki Vareki, Saman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 8 vom: 06. Aug., Seite 2121-2132 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:8 |g day:06 |g month:08 |g pages:2121-2132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02453-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 8 |b 06 |c 08 |h 2121-2132 | ||